Currently Viewing
Investigational Drug Effective in Treating Resistant GIST, Colorectal Cancer
June 07, 2012 – Elizabeth Whittington
New findings on chemotherapy for breast cancer
June 05, 2012 – Debu Tripathy
ASCO wrap-up
June 05, 2012 – Jon Garinn
Perseverence above all else
June 03, 2012 – Jon Garinn
Lower survival for young adult ALL patients
June 03, 2012 – Katherine Lagomarsino
HPV status in head and neck cancer may affect treatment decisions
June 03, 2012 – Elizabeth Whittington
Avastin and olaparib may get a second chance in ovarian cancers
June 03, 2012 – Elizabeth Whittington
Another breakthrough in immunotherapy
June 02, 2012 – Debu Tripathy
The molecular era of cancer
June 02, 2012 – Katherine Lagomarsino

Investigational Drug Effective in Treating Resistant GIST, Colorectal Cancer

Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies for GIST and metastatic colorectal cancer.

BY Elizabeth Whittington
PUBLISHED June 07, 2012
Patients with GIST, a rare gastrointestinal sarcoma, benefited from major advancements in chronic myelogenous leukemia when Gleevec (imatinib) revolutionized therapy for both cancers a decade ago. Now, an experimental drug in metastatic colorectal cancer may have the same effect. Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies.

In the GIST study, progression-free survival was extended from less than one month on placebo to 4.8 months on regorafenib. Patients in the placebo group whose cancers progressed were allowed to receive regorafenib. Because patients were allowed to cross over from the placebo group to regorafenib, the trial did not produce a statistically significant overall survival difference; however, researchers noted a trend for longer survival with regorafenib.

In the CORRECT trial, patients with colorectal cancer who received regorafenib also saw an improvement in median overall survival (6.4 months versus 5 months).

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Gastrointestinal stromal tumor CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In